PRF Technologies Advances OcuRing-K Intraocular Ring for Cataract Surgery Through Phase I Safety Studies
核心洞察
PRF Technologies (搜索) acquired LayerBio (搜索) in August 2025, adding OcuRing-K (搜索), a bio-erodible sustained-release intraocular ring designed to deliver ketorolac during cataract (搜索) surgery through a single application.
Preclinical studies and Phase I clinical evaluation demonstrated a favorable safety profile with no treatment-related serious adverse events observed for the drop-less therapy platform.
The company completed IND-supporting tests and validations in 2025 for a Phase II study of OcuRing-K (搜索), targeting the large global cataract (搜索) surgery market.
PRF Technologies (搜索) Ltd. has advanced its OcuRing-K (搜索) intraocular drug delivery system through Phase I safety studies, positioning the company to address compliance challenges in post-cataract (搜索) surgery care. The bio-erodible sustained-release ring demonstrated a favorable safety profile with no treatment-related serious adverse events observed in preclinical studies and Phase I clinical evaluation, according to data reported in January 2026.
Strategic Acquisition Expands Ophthalmic Pipeline
PRF Technologies (搜索) completed its majority investment in Boston-based LayerBio (搜索) in August 2025, acquiring the OcuRing-K (搜索) program and broadening the company's focus beyond post-operative pain into ophthalmology and sustained-release ocular drug delivery. The acquisition was designed to expand PRF's pipeline through new technologies and create synergies with existing clinical-development activities.
OcuRing-K (搜索) represents a patent-protected approach to delivering ketorolac during cataract (搜索) surgery through a single intraoperative application, with the goal of reducing or eliminating the need for post-surgical eye drops. The device addresses a significant clinical challenge, as existing post-operative treatment often depends on complex eye-drop regimens with poor compliance and inconsistent delivery.
Clinical Development Progress
During 2025, PRF conducted the tests and validations required for submission of an Investigational New Drug (IND) application for a Phase II study of OcuRing-K (搜索). Work is progressing toward the next clinical trial, building on the positive safety data from earlier studies.
The company believes OcuRing-K (搜索) represents a particularly attractive opportunity because cataract (搜索) surgery is one of the most commonly performed procedures globally. The sustained-release platform may also support broader ophthalmic indications over time, including additional NSAID, steroid, antibiotic and anti-VEGF applications.
Platform Technology Potential
Research and development findings confirmed that LayerBio (搜索)'s sustained-release ocular platform can accommodate multiple drug entities, including corticosteroids and NSAIDs, reinforcing the platform's longer-term potential beyond OcuRing-K (搜索) alone. This versatility positions the technology for potential expansion across various ophthalmic therapeutic areas.
Dr. Ehud Geller, Executive Chairman of PRF Technologies (搜索), commented, "In healthcare, we significantly strengthened our pipeline and strategic focus through our majority investment in LayerBio (搜索) and the continued advancement of OcuRing-K (搜索), which we believe has the potential to address a large unmet need in cataract (搜索) surgery through a truly drop-less, sustained-release approach."
Financial Performance
PRF Technologies (搜索) reported research and development expenses of approximately $1.1 million for the year ended December 31, 2025, compared to approximately $11.7 million for 2024. The decrease was primarily due to extensive clinical trial costs in 2024, partially offset by additional research and development expenses incurred in connection with LayerBio (搜索) activities.
The company ended 2025 with approximately $4.1 million in cash, cash equivalents, short-term deposits and restricted cash, and positive working capital of approximately $1.9 million. During 2025, PRF completed at-the-market issuances that generated approximately $4.0 million in gross proceeds.
Net loss for 2025 was approximately $4.8 million, compared to a net loss of approximately $14.6 million for 2024, reflecting the reduced clinical trial expenses and operational adjustments following the LayerBio (搜索) acquisition.